Biopharma News

AbbVie to pay Shire $1.636 billion break fee for terminating purchase agreement.

A Priority Review voucher Sanofi and Regeneron purchased from BioMarin pharmaceuticals may put their mAb ahead of Amgen's in the market.

Lilly announces the closure of its Guayama, Puerto Rico manufacturing facility amid continued investments at other plants.

Pfizer's addition of a new vaccine suite and multiproduct bioprocess suite to its Ireland facility win the company the title of 2014 Facility of the Year.

Sanofi Pasteur and Immune Design agree to jointly develop therapies through Phase II clinical trials.

AbbVie sends Shire notice that it is reconsidering its offer recommendation.

FDA granted Genentech priority review for its diabetic retinopathy treatment, Lucentis.

GSK is found guilty of offering bribes to doctors and is fined $489 million.

Baxter announced that its new biopharmaceutical company will be named Baxalta when the company separates into two publicly traded companies in mid-2015.

ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.

Pfizer announced that FDA approved ELELYSO for treatment of Type 1 Gaucher disease in adult and pediatric patients.

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

CPhI 2014 panel additions to provide global insights from the contract services sector.

After rejecting several bids, Shire has agreed to a merger with AbbVie valued at almost $55 billion.

FDA grants breakthrough therapy designation to Novartis chimeric antigen receptor therapy.

PlantForm and PharmaPraxis announce plans to develop six biopharmaceutical targets for the Brazilian market.

Genentech's $1.7 billion acquisition of Seargon Pharmaceutical includes portfolio of investigational next-generation oral selective estrogen receptor degraders.

The collaboration will use Mersana Therapeutics Fleximer technology for antibody-drug conjugates.

Merck funds Bionomics with $20 million to progress therapies for cognitive impairment caused by central nervous system disorders

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

GSK and Save the Children announce criteria for awards that recognize innovation in healthcare for the world"s poorest children.

Cytovance Biologics completes GMP manufacture of ARMO BioSciences' lead product.

Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.

Shire reports that AbbVie offer undervalued company.

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

Merck acquires Idenix Pharmaceuticals for $3.85 billion.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.